Showing results (1451-1460 of 8,142) with videos related to

Sort By:
Pageof 815
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Haematologica|June 7, 2021
IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation loadDianna Hussmann, Anna Starnawska, Louise Kristensen, et al.
Haematologica|June 24, 2021
Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file studyHildegard T Greinix, Dirk-Jan Eikema, Linda Koster, et al.
Haematologica|June 24, 2021
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphomaSara Napoli, Luciano Cascione, Andrea Rinaldi, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
Haematologica|June 1, 2022
Treatment of inherited thrombocytopeniasCarlo L Balduini
Haematologica|December 1, 2022
Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severityEdwige Tellier, Agnès Widemann, Raphaël Cauchois, et al.
Haematologica|December 1, 2022
DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphomaLianqun Qiu, Guilin Tang, Shaoying Li, et al.
Haematologica|December 1, 2022
ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA studyDavid Sibon, Bettina Bisig, Christophe Bonnet, et al.
Haematologica|December 15, 2022
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidineTheodoros Karantanos, Patric Teodorescu, Marios Arvanitis, et al.
Pageof 815